China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
 Announces Annual Meeting of Stockholders - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., March 21, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59 p.m., Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to [email protected] if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Citigate Dewe Rogerson +1 347 481-3711 [email protected]
